RHEACELL

RHEACELL is a German biotech leader advancing a late-stage pipeline of allogeneic, off-the-shelf stem cell therapies based on its proprietary ABCB5+ mesenchymal stromal cell platform. The company's lead program targets recessive dystrophic epidermolysis bullosa (RDEB) in a pivotal Phase 3 trial and already holds national marketing authorization in Germany for chronic venous ulcers (AMESANAR®). With over 20 years of foundational research, in-house GMP manufacturing, a strong IP portfolio, and strategic partnerships like the 2025 alliance with AOP Health, RHEACELL is positioned to address significant orphan and rare disease markets through its immunomodulatory and tissue-regenerative therapeutics.

Proprietary platform using allogeneic, off-the-shelf ABCB5+ mesenchymal stromal cells (MSCs) as a pure drug substance for immunomodulation and tissue regeneration. Features in-house GMP manufacturing and a strong IP portfolio.

RHEACELL competes in the mesenchymal stromal cell therapy space, facing competition from other biotechs developing allogeneic MSC therapies for inflammatory and wound indications (e.g., Mesoblast, Pluristem). For RDEB, it competes with gene therapy and protein-based approaches. Its key differentiators are the specific ABCB5+ cell subset, systemic administration for RDEB, and full in-house manufacturing control.